Identification of patients with locally advanced rectal cancer eligible for neoadjuvant chemotherapy alone: Results of a retrospective study

被引:4
作者
Han, Yi-min [1 ]
Qi, Wei-xiang [1 ]
Wang, Shu-bei [1 ]
Cao, Wei-guo [1 ]
Chen, Jia-yi [1 ]
Cai, Gang [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Radiat Oncol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Radiat Oncol, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 12期
关键词
neoadjuvant chemoradiation; neoadjuvant chemotherapy; radiation therapy; rectal cancer; TOTAL MESORECTAL EXCISION; PREOPERATIVE CHEMORADIOTHERAPY; OPEN-LABEL; POSTOPERATIVE CHEMORADIOTHERAPY; GERMAN CAO/ARO/AIO-04; ADJUVANT CHEMOTHERAPY; RADIOTHERAPY; MULTICENTER; OXALIPLATIN; CAPECITABINE;
D O I
10.1002/cam4.6029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives: Neoadjuvant chemotherapy (nCT) appears in a few clinical studies as an alternative to neoadjuvant chemoradiation (nCRT) in selected patients with locally advanced rectal cancer (LARC). We aimed to compare the clinical outcomes of nCT with or without nCRT in patients with LARC and to identify patients who may be suitable for nCT alone.Materials and Methods: A total of 155 patients with LARC who received neoadjuvant treatment (NT) were retrospectively analysed from January 2016 to June 2021. The patients were divided into two groups: nCRT (n = 101) and nCT (n = 54). More patients with locally advanced disease (cT4, cN+ and magnetic resonance imaging-detected mesorectal fascia [mrMRF] positive [+]) were found in the nCRT group. Patients in the nCRT group received a dose of 50 Gy/25 Fx irradiation with concurrent capecitabine, and the median number of nCT cycles was two. In the nCT group, the median number of cycles was four.Results: The median follow-up duration was 30 months. The pathologic complete response (pCR) rate in the nCRT group was significantly higher than that in the nCT group (17.5% vs. 5.6%, p = 0.047). A significant difference was observed in the locoregional recurrence rate (LRR); 6.9% in the nCRT group and 16.7% in the nCT group (p = 0.011). Among patients with initial mrMRF (+) status, the LRR in the nCRT group was significantly lower than that in the nCT group (6.1% vs. 20%, p = 0.007), but not in patients with initial mrMRF negative (-) (10.5% in each group, p = 0.647). Compared with the nCT group, a lower LRR was observed in patients in the nCRT group with initial mrMRF (+) converted to mrMRF (-) after NT (5.3% vs. 23%, p = 0.009). No significant difference was observed between the two groups regarding acute toxicity and overall and progression-free survivals. Multivariate analysis showed that nCRT and ypN stage were independent prognostic factors for the development of LRR.Conclusion: Patients with initial mrMRF (-) may be suitable for nCT alone. However, patients with initial mrMRF (+) converted to mrMRF (-) after nCT are still at high risk of LRR, and radiotherapy is recommended. Prospective studies are required to confirm these findings.
引用
收藏
页码:13309 / 13318
页数:10
相关论文
共 37 条
[1]  
Amin M. B, 2017, AJCC Cancer Staging Manual
[2]   Neoadjuvant chemoradiation in locally advanced rectal cancer: the surgeon's perspective [J].
Azin, Arash ;
Khorasani, Mohammadali ;
Quereshy, Fayez A. .
JOURNAL OF CLINICAL PATHOLOGY, 2019, 72 (02) :133-134
[3]   Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial [J].
Bahadoer, Renu R. ;
Dijkstra, Esmee A. ;
van Etten, Boudewijn ;
Marijnen, Corrie A. M. ;
Putter, Hein ;
Kranenbarg, Elma Meershoek-Klein ;
Roodvoets, Annet G. H. ;
Nagtegaal, Iris D. ;
Beets-Tan, Regina G. H. ;
Blomqvist, Lennart K. ;
Fokstuen, Tone ;
ten Tije, Albert J. ;
Capdevila, Jaume ;
Hendriks, Mathijs P. ;
Edhemovic, Ibrahim ;
Cervantes, Andres ;
Nilsson, Per J. ;
Glimelius, Bengt ;
van de Velde, Cornelis J. H. ;
Hospers, Geke A. P. .
LANCET ONCOLOGY, 2021, 22 (01) :29-42
[4]   Chemotherapy with preoperative radiotherapy in rectal cancer [J].
Bosset, Jean-Francois ;
Collette, Laurence ;
Calais, Gilles ;
Mineur, Laurent ;
Maingon, Philippe ;
Radosevic-Jelic, Ljiljana ;
Daban, Alain ;
Bardet, Etienne ;
Beny, Alexander ;
Ollier, Jean-Claude .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (11) :1114-1123
[5]   Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data [J].
Breugom, Anne J. ;
Swets, Marloes ;
Bosset, Jean-Francois ;
Collette, Laurence ;
Sainato, Aldo ;
Cionini, Luca ;
Glynne-Jones, Rob ;
Counsell, Nicholas ;
Bastiaannet, Esther ;
van den Broek, Colette B. M. ;
Liefers, Gerrit-Jan ;
Putter, Hein ;
van de Velde, Cornelis J. H. .
LANCET ONCOLOGY, 2015, 16 (02) :200-207
[6]   Magnetic Resonance of Rectal Cancer Response to Therapy: An Image Quality Comparison between 3.0 and 1.5 Tesla [J].
Caruso, Damiano ;
Zerunian, Marta ;
De Santis, Domenico ;
Biondi, Tommaso ;
Paolantonio, Pasquale ;
Rengo, Marco ;
Bellini, Davide ;
Ferrari, Riccardo ;
Ciolina, Maria ;
Lucertini, Elena ;
Polici, Michela ;
Iannicelli, Elsa ;
Tombolini, Vincenzo ;
Laghi, Andrea .
BIOMED RESEARCH INTERNATIONAL, 2020, 2020
[7]   Cancer incidence and mortality in China, 2007 [J].
Chen, Wan-qing ;
Zeng, Hong-mei ;
Zheng, Rong-shou ;
Zhang, Si-wei ;
He, Jie .
CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (01) :1-8
[8]   Dynamic contrast-enhanced magnetic resonance imaging in locally advanced rectal cancer: role of perfusion parameters in the assessment of response to treatment [J].
Ciolina, Maria ;
Caruso, Damiano ;
De Santis, Domenico ;
Zerunian, Marta ;
Rengo, Marco ;
Alfieri, Norma ;
Musio, Daniela ;
De Felice, Francesca ;
Ciardi, Antonio ;
Tombolini, Vincenzo ;
Laghi, Andrea .
RADIOLOGIA MEDICA, 2019, 124 (05) :331-338
[9]   Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial [J].
Conroy, Thierry ;
Bosset, Jean-Francois ;
Etienne, Pierre-Luc ;
Rio, Emmanuel ;
Francois, Eric ;
Mesgouez-Nebout, Nathalie ;
Vendrely, Veronique ;
Artignan, Xavier ;
Bouche, Olivier ;
Gargot, Dany ;
Boige, Valerie ;
Bonichon-Lamichhane, Nathalie ;
Louvet, Christophe ;
Morand, Clotilde ;
de la Fouchardiere, Christelle ;
Lamfichekh, Najib ;
Juzyna, Beata ;
Jouffroy-Zeller, Claire ;
Rullier, Eric ;
Marchal, Frederic ;
Gourgou, Sophie ;
Castan, Florence ;
Borg, Christophe .
LANCET ONCOLOGY, 2021, 22 (05) :702-715
[10]   Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial [J].
Deng, Yanhong ;
Chi, Pan ;
Lan, Ping ;
Wang, Lei ;
Chen, Weiqing ;
Cui, Long ;
Chen, Daoda ;
Cao, Jie ;
Wei, Hongbo ;
Peng, Xiang ;
Huang, Zonghai ;
Cai, Guanfu ;
Zhao, Ren ;
Huang, Zhongcheng ;
Xu, Lin ;
Zhou, Hongfeng ;
Wei, Yisheng ;
Zhang, Hao ;
Zheng, Jian ;
Huang, Yan ;
Zhou, Zhiyang ;
Cai, Yue ;
Kang, Liang ;
Huang, Meijin ;
Peng, Junsheng ;
Ren, Donglin ;
Wang, Jianping .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) :3300-+